natgillin/translations-raw huggingface dataset:
a cylinder for storing salt in solid form, the cylinder being suitable for being supplied directly by the pipeline of water to be treated under pressure, the cylinder comprising one or more tubes forming one or more electrolysis chambers; 
- cilindar (16) koji sadrži sol NaCl u čvrstom obliku, pri čemu je navedeni cilindar (16) konfiguriran za dovod vode koja dolazi izravno iz kanalizacijskog voda za vodu koja se obrađuje pod tlakom kako bi se dobila voda zasićena sa soli NaCl ili slanom otopinom, naznačen time što
Liquid inks have typical viscosity values in the range of 0.1 to 5 Pa*s at 20°C, and allow for an easy orientation of the magnetic pigment. 
Tekuće tinte imaju tipične vrijednosti viskoziteta u rasponu od 0,1 do 5 Pa*s na temperaturi od 20 X 1 omogućuju lako usmjeravanje magnetskog pigmenta.
Advantageously, the concentration of said carboxylic acid(s) in said fluid may according to the present invention be at least 100 part per million by weight, such as at least 250 part per million by weight, and preferably at least 400 parts per million by weight, such as at least 500 parts per million by weight. 
Metoda u skladu s bilo kojim od patentnih zahtjeva 44-46, pri čemu je koncentracija navedene karboksilne(ih) kiseline(a) u navedenoj tekućini najmanje 100 dijelova na milijun prema težini, kao što je najmanje 250 dijelova na milijun prema težini, a poželjno najmanje 400 dijelova na milijun prema težini, kao što je 500 dijelova na milijun prema težini.
In the conventional pelletization methods the ratio of the product fraction is about 60% by weight. 
U standardnim metodama granuliranja udio frakcije produkta iznosi oko 60% (težinski).
The method of E36, wherein the squamous tumor is selected from the group consisting of squamous lung tumor, a squamous tumor of the head or neck, and a squamous cervical tumor. 
Formulacija za uporabu prema zahtjevu 21, naznačena time što je skvamozni tumor odabran iz skupine koja se sastoji od skvamoznog tumora pluća, skvamoznog tumora glave ili vrata i skvamoznog tumora vrata maternice.
Compounds of formula (I) may be useful for the treatment of any conditions in which inhibition of matrix metalloproteinase would be beneficial, especially in the treatment of inflammatory diseases and autoimmune disorders. 
Spojevi formule (14), (Ib) 1 (Ic) mogu biti korisni u liječenju bilo kojeg stanja kod kojeg bi bila povoljna inhibicija matrične metaloproteinaze, osobito kod liječenja upalnih bolesti i autoimunih poremećaja.
These substances which conventionally irritate the nasal passages and/or pharynx may also bring about a very unpleasant sensation or even unbearable pain when administered parenterally, in particular intravenously, such that the abuser does not wish to or cannot continue taking the substance. 
Ove tvari koje uobičajeno nadražuju šupljinu nosa i/ili ždrijela mogu i kod parenteralne, osobito intravenozne primjene prouzročiti vrlo neugodan osjećaj do nepodnošljivih bolova, tako da zlorabitelj neće ili ne može dulje nastaviti uzimanje.
The computer system of claim 13, wherein the first program is a host program and the second program is a guest program, the guest program having access to shared resources of the computing environment during a timeslice provided to a guest central processing unit on which the guest program executes, the grace period being distinguishable from the timeslice. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što gostujući operativni sustav ima pristup dijeljenim resursima računalnog okoliša u odsječku vremena osiguranom za gostujući središnji procesor na kojem gostujući operativni sustav izvršava, gdje se razdoblje počeka razlikuje od odsječka vremena.
(XIIb) reacting an intermediate of formula (XXIV') with HR9 in the presence of a suitable base and a suitable solvent, With R1, R2, R1a, R9 and n as defined in claim 1; 
(XIIb) reakcija intermedijera formule (XXIV’) s HR9 u prisutnosti prikladne baze i prikladnog otapala, [image] s R1, R2, R1a, R9 i n kako su definirani u zahtjevu 1;
The pharmaceutical composition for use according to any one of the preceding claims, wherein said naltrexone or pharmaceutically acceptable salt thereof and said bupropion or pharmaceutically acceptable salt thereof are administered for at least 28 weeks. 
Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da se navedeni naltrekson ili njegova farmaceutski prihvatljiva sol i navedeni bupropion ili njegova farmaceutski prihvatljiva sol daju tijekom najmanje 28 tjedana.
The isolated fusion protein of para 14, wherein the fusion protein requires less frequent dosing or reduced comparable dosage to achieve or maintain a circulating blood level in a subject compared to biologically active protein not linked to the XTEN that is administered to a subject in a comparable fashion. 
Izolirani fuzijski protein prema jednom od zahtjeva 5 do &, naznačen time, da fuzijski protein zahtijeva doziranje s manjom učestalošću ili smanjenu usporedivu dozu, u svrhu postizanja ili održavanja cirkulacijske razine krvi kod pojedinca, u usporedbi prema biološki aktivnom proteinu koji nije povezan s XTEN-om, koja će se primjenjivati kod pojedinca na usporedbeni način.
The motorized buoy of claim 1, wherein the buoy is configured to be launched by dropping the buoy from a height of at least 20 feet. 
Motorizirana bova prema zahtjevu 1, naznačena time, da je bova oblikovana tako, da _se može spustiti u vodu pomoću izbacivanja bove s visine od najmanje 20 stopa.
The process of claim 6, wherein step (f')(iii) comprises the steps: 
Korak spajanja (e’) sadrži korake:
To a solution of compound 52 (8.1 g, 32.3 mmol) in ethanol (55 mL) was added palladium on carbon (10%, 750 mg). 
U otopinu spoja 52 (8,1 g, 32,3 mmol) u etanolu (55 mL) doda se paladij na ugljenu (10%, 750 mg).
the casement window or framework respectively comprises at least four hollow-chamber profiles based on PVC-U, as well as a fire resistant insert mounted in the casement window or framework respectively, more particularly a fire resistant glazing; 
prozorska okna ili okviri obuhvaćaju najmanje četiri šuplja profila na bazi PVC-U, kao i vatro-otporni umetak ugrađen u prozorsko okno ili okvir, točnije vatro-otporni premaz;
where the compound of formula (I) contains a methyl group, an hydroxymethyl derivative thereof (—CH3→—CH2OH): 
(il) s aminom HN(R')(R*) za dobivanje spoja sljedeće formule (II): 8
A compound according to claim 1, wherein R1 is a direct-bonded or —O-linked saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ring containing 1, 2, 3 or 4 atoms selected from N, O, and S, but containing no more than one O or S, wherein the available carbon atoms of the ring of substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0 or 1 R2 substituents, and the ring is additionally substituted by 0, 1, 2 or 3 substituents independently selected from halo, nitro, cyano, C1-4alkyl, OC1-4alkyl, OC1-4haloalkyl, NHC1-4alkyl, N(C1-4alkyl)C1-4alkyl and C1-4haloalkyl. 
Spoj prema patentnom zahtjevu 1, naznačen time što R' je direktno vezani ili kisikom vezani zasićeni, djelomično zasićeni ili nezasićeni 5-, 6- ili 7-člani monociklični prsten koji sadrži 1, 2, 3 ili 4 atoma izabrana od N, 0 1 S, ali koji ne sadrži više od jednog O ili S, pri čemu su dostupni atomi ugljika u prstenu supstituirani sa 0, 1 ili 2 okso ili tiokso grupe, gdje je prsten supstituiran sa 0 ili 1 R* supstituentom, i prsten je dodatno supstituiran sa 0, 1, 2 ili 3 supstituenta nezavisno izabrana od halo, nitro, cijano, C,agalkil, OC,4alkil, OCi4haloalkil, NHC,.galkil, N(C,4alkiDC,salkil 1 Ci. ahaloalkil.
Non-aqueous media like ether, ethyl acetate, isopropanol or acetonitrile are generally preferred. 
Ne-vodeni mediji kao eter, etil acetat, izopropanol ili acetonitril imaju općenito prednost.
The polypeptide of claim 8, wherein the polypeptide exhibits a fibrinolytic activity that is inhibited by a2-antiplasmin at a rate of inhibition that is at least about 5- fold faster than the rate of inhibition of the fibrinolytic activity of mini-plasmin by a2-antiplasmin. 
Polipeptid prema zahtjevu 8, naznačen time da polipeptid pokazuje fibrinolitičku aktivnost koja je inhibirana s a2- antiplazminom pri stupnju inhibicije koji je najmanje oko 5 puta brži nego što je stupanj inhibicije fibrinolitičke aktivnosti mini-plazmina sa 62-antiplazminom.
A tetrahydroisoquinolin-1-one derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof: [the symbols in the formula represent the following meanings: 
Derivat tetrahidroizokinolin-1-ona predstavljen formulom (I) ili njegova farmaceutski prikladna sol:
represents a C1-C6 alkyl group; for use in the prevention or treatment of an ataxic disorder, in particular a spinocerebellar ataxic disorder. 
R' predstavlja skupinu C-CÂ« alkil; naznačen time da je za upotrebu u prevenciji ili liječenju ataksičnog poremećaja.
Use of claim 1, wherein HIV titer in the subject infected with HIV is decreased after contacting the subject with the isolated polypeptide. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time što so HIV titar kod subjekta inficiranog HIV-om smanjuje nakon kontaktiranja subjekta s izoliranim polipeptidom.
Still more preferred corticosteroids under the present invention are: budesonide, beclomethasone dipropionate, mometasone furoate, ciclesonide, triamcinolone, triamcinolone acetonide, triamcinolone hexaacetonide and fluticasone propionate optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinirani lijekovi mogu se prema tome davati jedanput na dan. Osobito poželjni lijekovi LABA su formoterol, salmeterol i GSK-597901, GSK-159797, KUL-1248, TA-2005 i QAB-149, po izboru u obliku njihovih racemata, enantiomera, dijastereomera i smjesa te adicijskih soli s farmakološki kompatibilnim kiselinama.
A compound of claims 21, 22, 23 or 24, wherein ring vertex d is N. 
Spoj u skladu s patentnim zahtjevom 21, 22, 23 ili 24, naznačen time, da je vrh prstena d N.
In another aspect of the invention, the suitable solvent used in the crystallization step is a mixture of ethyl acetate and i -propanol. 
Poželjno, prikladno otapalo koja se koristi u kristalizacijskom koraku je smjesa etil acetata 1 i-propanola.
is deficient in mismatch DNA repair pathway, optionally wherein the cancer cells are deficient in MutS, MutH and MutL; or 
je deficitaran u pogledu puta popravka neusklađene DNK, pri čemu su stanice raka opcionalno deficitarne u pogledu Mut$, MutH i Murl; ili
An ink cartridge (3) according to any preceding claim, wherein the electrical circuit is sunken with respect to the front face so that electrical contact is made after other interfaces are connected. 
Uložak za tintu (3) u skladu s patentnim zahtjevom 12, naznačen time što električni krug (19) ulazi u prednju površinu uloška (33), tako da se električni kontakt uspostavi nakon povezivanja drugih sučelja.
Edges of the metal part/layer may be bent or curled so as to reinforce its stiffness. 
Rubovi metalnog dijela/sloja mogu se saviti ili zafrkati tako da se pojača njegova krutost.
The term “carboxy” or “carboxyl” denotes the group —CO2H; also referred to as a carboxylic acid group. 
Izraz "karboksi "' ili "karboksil " označava skupinu -CO;H; također nazivanu i skupina karboksilne kiseline.
The floating structure of claim 1, further comprising a propulsion apparatus and at least one conduit connecting between the fuel tank and the propulsion apparatus for supplying fuel from the fuel tank to the propulsion apparatus for consumption in the propulsion apparatus. 
Plutajuća struktura sa spremnikom za plinovito gorivo (104) prema zahtjevu 3, naznačena time da je strojarnica za obradu goriva koje je pohranjeno u spremniku za plinovito gorivo smještena preko spremnika za plinovito gorivo i nepropusna pregrada je smještena između strojarnice i područja kabine.
It is clear that these results have been made possible thanks to the fine grain microstructure with homogeneous development of the grain in every direction, or of the polygonal type, with complete separation of the iron carbides from the ferritic grains. 
Jasno je da su ovi rezultati mogući zahvaljujući finoj mikrostrukturi zrna sa homogenim razvojem zrna u svim pravcima, ili poligonalnog tipa, sa potpunim odvajanjem karbida željeza od feritnih zrna.
The solution is filtered and the titled product is recrystallised from water/IPA as a white/pale green crystals. 
Otopinu se profiltrira i naslovni proizvod se prekristalizira iz voda/IPA kao bijelo/blijedo zeleni kristali.
(e′) coupling the compound of formula (XVIII) with a compound of formula (XIXa): 
spajanje spoja formule (XVIII) sa spojm formule (XIX);
one or more bags, 
- jednu ili više vreća,
The active agent in lozenges of the invention may be stable for up to three months, up to six months, up to nine months, up to twelve months, or up to eighteen months. 
Aktivno sredstvo u tabletama prema izumu može biti stabilno do tri mjeseca, do Å est mjeseci, do devet mjeseci, do dvanaest mjeseci ili do osamnaest mjeseci.
separating said beads (9) from said colloidal suspension, and 
razdvajanje navedenih zrnaca (9) iz navedene koloidne suspenzije, te
Plastic container with drying unit at 40°C and 75% RH 
Plastičnom spremniku s jedinicom za sušenje, na 40 *C, uz 75 % relativne vlage
transmitting said further relay message towards said remote location. 
- - odašiljanja spomenute sljedeće relejne poruke (S3) prema spomenutoj udaljenoj lokaciji.
is a phenyl or thiophenyl, wherein any phenyl or thiophenyl of R1 is optionally substituted with one or more groups independently selected from fluoro, chloro and -CN; and 
je fenil ili tiofenil, pri čemu je bilo koji fenil ili tiofenil iz skupine R1 opcionalno supstituiran s jednom ili više skupina zasebno odabranih iz fluoro skupine, kloro skupine i −CN; i
Layer 1: comprising about 33.3% w/w PLA, 33.3% w/w PBSA and 33.3% w/w PBAT; 
Višeslojna biorazgradiva folija prema zahtjevu 1, naznačena time da se sloj 1 sastoji iz 33,3% tež./tež PLA, 33,3% tež./tež. PBS i 33,3% tež./tež.
(b3.1) piercing a bottom wall of the cup-shaped body; (b3.2) sealing the opening thus obtained by means of a gas-impermeable film made of a multilayer preferably comprising a layer made of aluminum and a layer made of polypropylene; 
(b3.1) probijanje donje stijenke kućišta u obliku čašice; (b3.2) brtvljenje tako dobivenog otvora pomoću višeslojnog sloja koji sadržava sloj od aluminija i sloj od polipropilena;
characterising, by the processor, the driving behaviour of the driver on a basis of the driver profile; and 
utvrđivanje (4) profila vozača (24) iz odabranog događaja; i određivanje (9) ponašanja u vožnji vozača temeljem vozačevog profila.
The process according to claim 6, wherein the transition metal compound is a palladium compound. 
Postupak prema zahtjevu 7, u kome je paladijev spoj, paladij (II) spoj.
about 1 pH unit below the pI of the polypeptide. 
oko 1 pH-jedinice ispod pI-vrijednosti monoklonskog protutijela.
The communication method according to claim 2, wherein the CQI reporting is performed on uplink resources assigned by the resource assignment information. 
Komunikacijska metoda sukladno zahtjevu 2, naznačena time da se izvješćivanje o CQI provodi na resursima uzlazne veze koji su dodijeljeni informacijama o raspoređivanju resursa.
In relation to the complex microflora, probiotics were defined by a group of experts convened by the Food and Agriculture Organisation of the United Nations (FAO). 
Å to se tiče složene mikroflore, probiotike je definirala skupina stručnjaka koje je angažirala Organizacija Ujedinjenih naroda za hranu i poljodjelstvo (Food and Agriculture Organisation, FAO).
The aqueous layer after washing with ethyl acetate (1x10 mL) is acidified to pH ~2 by dropwise addition of dil. HCl. 
Vodeni sloj se nakon ispiranja etil-acetatom (1 x 10 ml) ukapavanjem razrijeđene HCI zakiseli do pH -2.
The method of claim 6, wherein the pharmaceutical composition is combined with a compound selected from the group consisting of memantine, amantadine, baclofen, R-baclofen, phenobam, acamprosate, bumetamide, carpipramine, oxytocin, vasopressin and mixtures thereof. 
Farmaceutski pripravak za njegovu upotrebu prema patentnom zahtjevu 3, naznačeno time da je kombiniran sa spojem odabranim iz skupine koju čine memantin, amantadin, baklofen, R-baklofen, fenobam, akamprosat, bumetanid, karpipramin, oksitocin, vazopresin i njihove smjese.
A combination of Claim 1 wherein the compound of formula Ia is selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1 naznačen time što je izabran iz grupe koju čine:
A lower molar ratio would reduce considerably the drawback of the expulsion of formaldehyde by the foam through time, but this cannot be achieved because said resins would not have the necessary stability in water. 
Manja molarna proporcija smanjila bi nedostatak, da pjena emitira s vremenom formaldehid, ipak to nije izvodijivo, jer takve smole ne bi imale potrebne postojanosti u vodi.
causing a reagent to flow through the holder for a period of time from 1 to 20 minutes. 
- < uzrokovanje protoka kroz držač u trajanju od 1 do 20 minuta.
A suspension formulation of claim 1 comprising a spray dried full length human IgG1 monoclonal antibody at a concentration from about 200 mg/mL to about 400 mg/mL suspended in a non-aqueous suspension vehicle with a viscosity less than about 20 centipoise at about 25°C, wherein the formulation has an average particle size from about 2 microns to about 10 microns, and injection glide force less than about 15 newton, and wherein the non-aqueous suspension vehicle comprises ethyl lactate. 
Suspenzijska formulacija prema zahtjevu 1, naznačena time, da obuhvaća monoklonalno ljudsko IgG1 protutijelo pune duljine, sušeno raspršivanjem, pri koncentraciji od oko 200 mg/mL do oko 400 mg/mL, koje je suspendirano u nevodenom suspenzijskom nosaču s viskozitetom manjim od oko 20 cP na oko 25°C, pri čemu formulacija ima prosječnu veličinu čestice od oko 2 mikrona do oko 10 mikrona, dok je injekcijska klizna sila manja od 15 N, te time, da nevodeni suspenzijski nosač obuhvaća etil-laktat.
The method according to claim 4, wherein the biomass comprises or originates from sugar cane, sugar beet, sweet sorghum, corn, wheat, barley, rye, sorghum, triticale, potato, sweet potato cassava, or a mixture thereof. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što biomasa sadrži šećernu trsku, šećernu repu, slatki sirak, kukuruz, pšenicu, ječam, raž, sirak, tritikale, krumpir, slatki krumpir, manioku, ili njihovu smjesu.
selecting one of said at least two initial paths according to a cost function, 
odabir (2006, 2008) jedne od navedene barem dvije početne putanje (302) prema funkciji troškova.
The compounds described in the present invention could be used to enhance the effects of cognition-enhancing agents, such as acetylcholinesterase inhibitors (e.g., tacrine), muscarinic receptor-1 agonists (e.g., milameline), nicotinic agonists, glutamic acid receptor (AMPA and NMDA) modulators, and nootropic agents (e.g., piracetam, levetiracetam). 
Spojevi opisani u prikazanom izumu mogu se upotrijebiti za pojačanje učinaka sredstava za kognitivno pojačanje, kao što su inhibitori acetilkolinesteraze (npr., takrin), antagonisti muskarinskog receptora-1 (npr., milamelin), agonisti nikotina, modulatori receptora glutaminske kiseline (AMPA i NMDA), nootropni agensi (npr., piracetam, levetiracetam).
immunizing a rodent of any one of claims 1 to 11, or a rodent made by the method of claim 12 with an antigen of interest; and obtaining a B cell expressing an antibody that binds to the antigen of interest with a desired affinity at a neutral pH while displaying reduced binding to the antigen of interest at an acidic pH and optionally (a) using the B cell to make a hybridoma or (b) isolating DNA encoding the antibody from the B cell or hybridoma and placing the DNA into expression vectors and transfecting the vectors into a host cell. 
Metoda za dobivanje antitijela koje izražava vezivanje ovisno o pH vrijednosti za interesni antigen koja se sastoji od: imunizacije glodavca prema bilo kojem zahtjevu od 1 do 11 ili glodavca dobivenog pomoću metode prema zahtjevu 12 s interesnim antigenom; 1 dobivanja B stanice koja izražava antitijelo koje se vezuje za interesni antigen sa željenim afinitetom pri neutralnoj pH vrijednosti uz ispoljavanje smanjenog vezivanja za interesni antigen pri kiseloj pH vrijednosti 1 opcionalno (a) korištenja B stanice za dobivanje hibridoma ili (b) izoliranja DNK koja šifrira antitijelo iz B stanice ili hibridoma i umetanje DNK u vektore ekspresije 1 transfektiranje vektora u stanicu domaćina.
An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. 
Vodeni farmaceutski pripravak koji sadrži tapentadol ili njegovu fiziološki prihvatljivu sol i prilagođen je za oralnu primjenu, pri čemu pripravak dodatno sadrži konzervans, pri čemu je sadržaj konzervansa najviše 90% sadržaja koji bi bio potreban u skladu s Ph .
A composition as claimed in Claim 8, wherein the cyclodextrin is 2-hydroxypropyl-B-cyclodextrin and is present at a concentration of 25%, and the buffer is 10 mM phosphate at pH 7.4. 
Pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin 2-hidroksipropil-B-ciklodekstrin i je prisutan u koncentraciji od 25%, a pufer je 10 mM fosfat s pH 7,4.
A process as claimed in claim 15 wherein the base A is selected from the group consisting of triethylamine, diisopropylethylamine, tri-n-butylamine, pyridine, 4-dimethylaminopyridine, NaOH, KOH, Na2CO3 and K2CO3. 
Postupak u skladu s patentnim zahtjevima 14 ili 15, naznačen time što baza A je trietilamin, diizopropiletilamin, tri-n-butilamin, piridin, 4-dimetilaminopiridin, NaOH, KOH, Na,CO: i K2CO».
The process according to claim 2, wherein the cleavage of the ketal or acetal group of compound of formula (V) is performed by acidic treatment in an aqueous medium, an organic solvent, or a mixture thereof. 
Postupak u skladu s patentni zahtjevi 2 ili 3, naznačen time što se odcjepljenje ketalne ili acetalne skupine iz spoja formule (V) provodi obradom kiselinom u vodenom mediju, u organskom otapalu ili u njihovoj smjesi.
The composition of any one of claims 10-13 or 19-22, or the single-molecule DNA-targeting RNA or polynucleotide encoding said single-molecule DNA-targeting RNA of any one of claims 14 or 19-22, or the one or more nucleic acids of any one of claims 15-17 or 19-22, for use in a method of therapeutic treatment of a patient. 
Sastav prema bilo kojem od zahtjeva 10 do 13, ili 19 do 22, RNK jednostruke molekule koja cilja na DNK ili polinukleotid koji kodira navedenu RNK jednostruke molekule koja cilja na DNK, prema zahtjevima 14 ili 19 do 22, jedna ili više nukleinskih kiselina prema bilo kojem od zahtjeva 15 do 17 ili 19 do 22, naznačeni time, da se upotrebljavaju u postupku terapeutske obrade pacijenta.
A space unit according to claim 1, characterized in that said furnishing equipment comprise a sofa unit (5) that is supported on said second supporting frame (4) and comprises a fixed seat portion (5b) and a backrest portion (5a). 
Prostorna jedinica sukladno zahtjevu 1, naznačena time, da navedeni namještaj za opremanje uključuje element sofe (5) koja se nalazi na drugom nosivom okviru (4), i sastoji se od fiksnog sjedećeg dijela (5b), i naslona (5a).